# Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

> **NCT07651163** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 450 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Lisaftoclax

## Interventions

- **DRUG:** Lisaftoclax+daunorubicin+cytarabine
- **DRUG:** Lisaftoclax+homoharringtonine+cytarabine+aclarubicin
- **DRUG:** Lisaftoclax+azacitidine
- **DRUG:** Lisaftoclax+ cytarabine
- **DRUG:** Lisaftoclax+azacitidine or azacitidine

## Key facts

- **NCT ID:** NCT07651163
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-01
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07651163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07651163, "Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07651163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*